{
    "url_original": "https://www.wsj.com/articles/novartis-to-buy-gene-therapy-company-targeting-eye-condition-11640176124?mod=business_lead_pos12",
    "url": "novartis-to-buy-gene-therapy-company-targeting-eye-condition-11640176124",
    "title": "Novartis to Buy Gene-Therapy Company Targeting Eye Condition",
    "sub_head": "Swiss healthcare giant to pay up to $1.5 billion for British biotech Gyroscope",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-456685?width=860&height=573",
    "image_1": "im-456685.jpg",
    "time": "2021-12-22 09:44:00",
    "body": "Novartis AG  has agreed to pay up to $1.5 billion to acquire British biotech Gyroscope Therapeutics, in a deal that will expand its pipeline of gene therapies targeting eye diseases.<br />The Swiss healthcare giant said Wednesday it would make an upfront payment of $800 million, and potential additional payments of up to $700 million, provided Gyroscope hits particular development milestones."
}